Verastem Inc. | Key People and Executives
Robert M. Forrester
President, Chief Executive Officer & Director
Brian Stuglik
Independent Director
Eric K. Rowinsky
Independent Director
Michael G. Kauffman
Lead Independent Director
Bruce J. Wendel
Independent Director
Alison Francis Lawton
Independent Director
Timothy Joseph Barberich
Independent Director
S. Louise Phanstiel
Independent Director
Robert M. Forrester
President, Chief Executive Officer & Director
Daniel W. Paterson
Chief Operating Officer
Robert E. Gagnon
Chief Financial Officer
Diep Le
Chief Medical Officer
Jonathan Pachter
Chief Scientific Officer
Ian W. Flinn
Director-Blood Cancer Research Program
Steven Bloom
Chief Strategy Officer
Joseph M. Lobacki
Chief Commercial Officer & Executive VP
Joseph Chiapponi
Vice President-Finance
Michael Ferraresso
Vice President-Commercial Operations
Hagop Youssoufian
Head-Hematology & Oncology Development
Brian Sullivan
Head-Corporate Development & Investor Relations
Cathy Carew
Vice President-Human Resources
Brian Stuglik
Independent Director
Eric K. Rowinsky
Independent Director
Michael G. Kauffman
Lead Independent Director
Bruce Jeffrey Wendel
Independent Director
Alison Francis Lawton
Independent Director
Timothy Joseph Barberich
Independent Director
S. Louise Phanstiel
Independent Director
| Address |
117 Kendrick Street
Needham Massachusetts 02494
United States
|
|
Employees
|
- |
| Website |
http://www.verastem.com |
| Updated |
07/08/2019 |
| Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs to treat cancer by the targeted killing of cancer stem cells. Its product candidates include duvelisib, which targets the Phosphoinositide 3-kinase signaling pathway; and defactinib, a targeted inhibitor of the Focal Adhesion Kinase signaling pathway. It evaluates these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. |
